NCT01381861: Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma |
|
|
| Completed | 2 | 23 | US | Carotuximab (TRC105), TRC105, NSC#754227 | Tracon Pharmaceuticals Inc. | Recurrent Ovarian Cancer, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma | 08/12 | 12/13 | | |